Sakuma Yuji, Matsukuma Shoichi, Yoshihara Mitsuyo, Nakamura Yoshiyasu, Noda Kazumasa, Nakayama Haruhiko, Kameda Yoichi, Tsuchiya Eiju, Miyagi Yohei
Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Kanagawa Cancer Center Hospital, Yokohama, Japan.
Am J Clin Pathol. 2007 Jul;128(1):100-8. doi: 10.1309/WVXFGAFLAUX48DU6.
Although adenocarcinomas of the lung are associated with epidermal growth factor receptor (EGFR) gene mutations and sensitivity to EGFR tyrosine kinase inhibitors, it remains unclear whether bronchioloalveolar carcinoma (BAC) components and/or subtypes affect these associations. We aimed to clarify correlations between EGFR gene mutations and BAC components and to establish the histologic features as reliable predictors for the mutations. We examined 141 non-small cell lung cancers (NSCLCs), including 118 adenocarcinomas, for mutations in exons 19 and 21 of the EGFR gene together with mutations in codon 12 of the K-ras gene using loop-hybrid mobility shift assays, a highly sensitive polymerase chain reaction-based method. Adenocarcinomas were subdivided into subtypes with a nonmucinous or mucinous BAC component and those without BAC components. In NSCLCs, EGFR mutations were detected in 75 cases (53.2%) and were significantly associated with adenocarcinoma, female sex, and never smoking. Among adenocarcinomas, nonmucinous and mucinous BAC components were significantly associated with EGFR and K-ras gene mutations, respectively. Because EGFR mutations were detected even in most pure nonmucinous BACs, ie, lung adenocarcinoma in situ, EGFR mutation is considered a critical event in the pathogenesis of nonmucinous BAC tumors.
虽然肺腺癌与表皮生长因子受体(EGFR)基因突变以及对EGFR酪氨酸激酶抑制剂的敏感性相关,但细支气管肺泡癌(BAC)成分和/或亚型是否影响这些关联仍不清楚。我们旨在阐明EGFR基因突变与BAC成分之间的相关性,并确定组织学特征作为这些突变的可靠预测指标。我们使用环杂交迁移率变动分析(一种基于聚合酶链反应的高灵敏度方法)检测了141例非小细胞肺癌(NSCLC),包括118例腺癌,以检测EGFR基因第19和21外显子的突变以及K-ras基因第12密码子的突变。腺癌被细分为具有非黏液性或黏液性BAC成分的亚型以及无BAC成分的亚型。在NSCLC中,75例(53.2%)检测到EGFR突变,且与腺癌、女性和从不吸烟显著相关。在腺癌中,非黏液性和黏液性BAC成分分别与EGFR和K-ras基因突变显著相关。由于即使在大多数纯非黏液性BAC(即原位肺腺癌)中也检测到EGFR突变,因此EGFR突变被认为是非黏液性BAC肿瘤发病机制中的关键事件。